Clinical Trials at Ohio State University Comprehensive Cancer Center
As of July 2026, 225 paid clinical trials are recruiting at Ohio State University Comprehensive Cancer Center, located at 300 W 10TH AVE, THE JAMES 9TH FLOOR RM. 924, COLUMBUS, OH 43210-1280, phone (614) 366-5332 in Columbus, Ohio. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Breast Cancer and Ovarian Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Columbus
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
227 clinical trials at Ohio State University Comprehensive Cancer Center
·Clear filters·A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer
Comparative Evaluation of Nicotine Analogs
A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
Prehabilitation Physical Therapy and Relaxation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery, ROAR-LCS Trial
Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms
A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Common conditions studied in Columbus
- Acute Myeloid Leukemia (20 active studies)
- Breast Cancer (19 active studies)
- Ovarian Cancer (18 active studies)
- Chronic Lymphocytic Leukemia (17 active studies)
- Endometrial Cancer (16 active studies)
- Stage IV Lung Cancer AJCC v8 (15 active studies)
Leading research sponsors in Columbus
- Ohio State University
- Ohio State University Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Nationwide Children's Hospital
- AstraZeneca
Frequently asked questions
How many paid clinical trials are currently recruiting in Columbus?
There are approximately 1,360 recruiting clinical trials in Columbus, Ohio listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Columbus pay participants?
Most recruiting trials in Columbus compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Columbus?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Columbus?
The most common conditions under active study in Columbus include Acute Myeloid Leukemia (20), Breast Cancer (19), Ovarian Cancer (18), Chronic Lymphocytic Leukemia (17), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Columbus?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Columbus on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Columbus?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Columbus?
Recruiting research sites in Columbus include Ohio State University Comprehensive Cancer Center, Nationwide Children's Hospital, The Ohio State University, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Columbus right now?
The largest active categories in Columbus are Cancer & tumors (488), Cardiovascular (76), Neurology & pain (66). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Ohio State University Comprehensive Cancer Center?
Ohio State University Comprehensive Cancer Center is located at 300 W 10TH AVE, THE JAMES 9TH FLOOR RM. 924, COLUMBUS, OH 43210-1280. Use the Google Maps link in the intro above to get directions.
How do I contact Ohio State University Comprehensive Cancer Center?
You can reach Ohio State University Comprehensive Cancer Center by phone at (614) 366-5332. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.